RTW Investments, LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), RTW Investments, LP reported 68 stock positions worth $6.8 billion. Its top holding was Rocket Pharmaceuticals (RCKT) at 7.0% of the portfolio, followed by Immunocore Holdings PLC-ADR (IMCR, 5.8%) and Axsome Therapeutics (AXSM, 5.3%). Compared with Q4 2023, it opened 15 new positions, sold out of 10, added to 25 and reduced 6. The biggest buy was Avidity Biosciences (RNAM, shares +19%) and the biggest sale an exit from Mirati Therapeutics (MRTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001493215
- Portfolio Value
- $6.8B (Q1 2024)
- SEC Filing
- 0001493152-24-019465 ↗ filed May 15, 2024
Holdings Value
Holdings 68 stocks · $6.8B
| RCKT Rocket Pharmaceuticals Inc. | 7.03% | 17,687,772 | $476.5M | No change |
| IMCR Immunocore Holdings PLC-ADR | 5.78% | 6,019,641 | $391.3M | Reduce -1.3% |
| AXSM Axsome Therapeutics Inc. | 5.29% | 4,492,679 | $358.5M | Add +0.1% |
| RARE Ultragenyx Pharmaceutical Inc. | 4.88% | 7,087,115 | $330.9M | Add +2.9% |
| BRKR Bruker Corp. | 4.64% | 3,344,095 | $314.1M | No change |
| ARGX Argenx SE - ADR | 3.88% | 667,195 | $262.7M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 3.77% | 13,829,315 | $255.7M | Add +22.9% |
| NTRA Natera Inc. | 3.50% | 2,593,323 | $237.2M | No change |
| PTCT PTC Therapeutics Inc. | 3.19% | 7,423,970 | $216.0M | No change |
| MASI Masimo Corp. | 3.17% | 1,462,400 | $214.8M | No change |
| RNAM Avidity Biosciences Inc. | 3.00% | 7,970,269 | $203.4M | Add +19.1% |
| MRUS Merus NV | 2.73% | 4,109,393 | $185.0M | Add +73.1% |
| CYTK Cytokinetics Inc. | 2.61% | 2,525,080 | $177.0M | No change |
| APGE Apogee Therapeutics Inc. | 2.42% | 2,467,591 | $164.0M | Add +15.2% |
| ALKS Alkermes PLC | 2.42% | 6,054,280 | $163.9M | Add +55.2% |
| PTGX Protagonist Therapeutics Inc. | 2.27% | 5,315,514 | $153.8M | No change |
| PEN Penumbra Inc. | 2.23% | 675,888 | $150.8M | Add +2.0% |
| AVDL Avadel Pharmaceuticals plc | 2.19% | 8,798,558 | $148.6M | Add +26.6% |
| AKRO Akero Therapeutics Inc. | 2.03% | 5,431,985 | $137.2M | Add +51.2% |
| ESTA Establishment Labs Holdings | 2.01% | 2,675,703 | $136.2M | Add +7.3% |
| ARVN Arvinas Inc. | 2.01% | 3,297,897 | $136.1M | Reduce -21.7% |
| TARS Tarsus Pharmaceuticals Inc. | 1.76% | 3,272,341 | $118.9M | Add +3.8% |
| SYK Stryker Corp. | 1.70% | 321,000 | $114.9M | New |
| MDGL Madrigal Pharmaceuticals Inc. | 1.57% | 397,047 | $106.0M | Reduce -51.3% |
| IMTX Immatics NV | 1.55% | 10,000,000 | $105.1M | Add +573.4% |
| SAGE Sage Therapeutics Inc. | 1.52% | 5,480,577 | $102.7M | Add +5.5% |
| SWAV Shockwave Medical Inc. | 1.39% | 288,684 | $94.0M | Add +343.7% |
| DYN Dyne Therapeutics Inc. | 1.30% | 3,091,587 | $87.8M | New |
| ETNB 89BIO Inc. | 1.27% | 7,378,548 | $85.9M | Add +32.3% |
| SYRE Spyre Therapeutics Inc. | 1.25% | 2,232,760 | $84.7M | No change |
| VCEL Vericel Corp. | 1.23% | 1,606,397 | $83.6M | Reduce -50.0% |
| CRGX Cargo Therapeutics Inc. | 1.23% | 3,735,619 | $83.4M | Reduce -27.8% |
| RDNT Radnet Inc. | 1.22% | 1,700,550 | $82.7M | Add +156.3% |
| TMO Thermo Fisher Scientific Inc. | 0.95% | 110,500 | $64.2M | Add +121.0% |
| TXG 10X Genomics Inc. Class A | 0.86% | 1,554,856 | $58.4M | Add +0.3% |
| STOK Stoke Therapeutics Inc. | 0.84% | 4,224,838 | $57.0M | Add +2.3% |
| FULC Fulcrum Therapeutics Inc. | 0.81% | 5,845,956 | $55.2M | Add +6.9% |
| TSHA Taysha Gene Therapies Inc. | 0.79% | 18,593,185 | $53.4M | Add +10.1% |
| INSM Insmed Inc. | 0.75% | 1,865,108 | $50.6M | No change |
| URGN Urogen Pharma Ltd. | 0.72% | 3,257,347 | $48.9M | Add +88.6% |
| KYTX Kyverna Therapeutics Inc. | 0.68% | 1,852,711 | $46.0M | New |
| ISRG Intuitive Surgical Inc. | 0.58% | 99,000 | $39.5M | New |
| NGNE Neurogene Inc. | 0.58% | 769,122 | $39.1M | New |
| JANX Janux Therapeutics Inc. | 0.56% | 1,000,000 | $37.6M | New |
| GHRS GH Research PLC | 0.52% | 3,327,129 | $35.5M | No change |
| OBIO Orchestra Biomed Holdings Inc. | 0.44% | 5,620,640 | $29.6M | No change |
| DNTH Dianthus Therapeutics Inc. | 0.30% | 666,667 | $20.0M | New |
| EPIX Essa Pharma Inc. | 0.29% | 2,298,662 | $19.5M | No change |
| LENZ Lenz Therapeutics Inc. | 0.28% | 863,389 | $19.3M | New |
| CGON CG Oncology Inc. | 0.27% | 413,670 | $18.2M | New |
| TRML Tourmaline Bio Inc. | 0.25% | 741,656 | $17.0M | Add +86.0% |
| ROIV Roivant Sciences Ltd. | 0.23% | 1,454,273 | $15.3M | No change |
| VRDN Viridian Therapeutics Inc. | 0.16% | 605,816 | $10.6M | No change |
| ACET Adicet Bio Inc. | 0.14% | 4,134,631 | $9.7M | No change |
| RGNX Regenxbio Inc. | 0.11% | 350,000 | $7.4M | New |
| SLRN Acelyrin Inc. | 0.10% | 978,310 | $6.6M | No change |
| EXAS Exact Sciences Corp. | 0.10% | 95,000 | $6.6M | New |
| ALLURION TECHNOLOGIES INC | 0.09% | 3,457,707 | $6.1M | No change |
| IMUX Immunic Inc. | 0.09% | 4,567,717 | $6.0M | Add +5.4% |
| MIST Milestone Pharmaceuticals Inc. | 0.09% | 3,256,102 | $5.8M | No change |
| GKOS Glaukos Corp. | 0.08% | 58,791 | $5.5M | New |
| SGMT Sagimet Biosciences Inc. Class A | 0.08% | 999,147 | $5.4M | New |
| LRMR Larimar Therapeutics Inc. | 0.07% | 650,000 | $4.9M | New |
| SABS Sab Biotherapeutics Inc. | 0.06% | 917,827 | $4.2M | No change |
| XGN Exagen Inc. | 0.04% | 1,504,602 | $2.4M | No change |
| XAIR Beyond Air Inc. | 0.03% | 1,204,820 | $2.1M | New |
| CUTRQ Cutera Inc. | 0.03% | 1,331,776 | $2.0M | Reduce -26.7% |
| ARYD Arya Sciences Acquisition-A | 0.02% | 127,970 | $1.4M | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $105K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 350,000 | $105K | No change |
Total filed on the 13F, all lines: $6.8B.
Portfolio Sells Q4 2023 → Q1 2024
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −6.21 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −4.91 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −2.15 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -51.3% | 1.57% | −1.38 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -1.3% | 5.78% | −0.73 |
| ARVN Arvinas Inc. | Reduce -21.7% | 2.01% | −0.70 |
| CRGX Cargo Therapeutics Inc. | Reduce -27.8% | 1.23% | −0.64 |
| VCEL Vericel Corp. | Reduce -50.0% | 1.23% | −0.55 |
| DHR Danaher Corp. | Sold out | 0.00% | −0.43 |
| SWTX Springworks Therapeutics Inc. | Sold out | 0.00% | −0.36 |
| TNGX Tango Therapeutics Inc. | Sold out | 0.00% | −0.30 |
| GH Guardant Health Inc. | Sold out | 0.00% | −0.21 |
| CUTRQ Cutera Inc. | Reduce -26.7% | 0.03% | −0.07 |
| APYX Apyx Medical Corp. | Sold out | 0.00% | −0.04 |
| SGHT Sight Sciences Inc. | Sold out | 0.00% | −0.01 |
| SIENTRA INC | Sold out | 0.00% | −0.00 |
Portfolio Buys Q4 2023 → Q1 2024
| RNAM Avidity Biosciences Inc. | Add +19.1% | 3.00% | +2.06 |
| MRUS Merus NV | Add +73.1% | 2.73% | +1.71 |
| SYK Stryker Corp. | New | 1.70% | +1.70 |
| APGE Apogee Therapeutics Inc. | Add +15.2% | 2.42% | +1.49 |
| IMTX Immatics NV | Add +573.4% | 1.55% | +1.31 |
| DYN Dyne Therapeutics Inc. | New | 1.30% | +1.30 |
| SWAV Shockwave Medical Inc. | Add +343.7% | 1.39% | +1.19 |
| ESTA Establishment Labs Holdings | Add +7.3% | 2.01% | +1.00 |
| RDNT Radnet Inc. | Add +156.3% | 1.22% | +0.86 |
| TARS Tarsus Pharmaceuticals Inc. | Add +3.8% | 1.76% | +0.76 |
| ALKS Alkermes PLC | Add +55.2% | 2.42% | +0.73 |
| AKRO Akero Therapeutics Inc. | Add +51.2% | 2.03% | +0.71 |
| KYTX Kyverna Therapeutics Inc. | New | 0.68% | +0.68 |
| AVDL Avadel Pharmaceuticals plc | Add +26.6% | 2.19% | +0.66 |
| ISRG Intuitive Surgical Inc. | New | 0.58% | +0.58 |
| NGNE Neurogene Inc. | New | 0.58% | +0.58 |
| JANX Janux Therapeutics Inc. | New | 0.56% | +0.56 |
| TMO Thermo Fisher Scientific Inc. | Add +121.0% | 0.95% | +0.53 |
| STOK Stoke Therapeutics Inc. | Add +2.3% | 0.84% | +0.50 |
| TSHA Taysha Gene Therapies Inc. | Add +10.1% | 0.79% | +0.32 |
| URGN Urogen Pharma Ltd. | Add +88.6% | 0.72% | +0.32 |
| DNTH Dianthus Therapeutics Inc. | New | 0.30% | +0.30 |
| ETNB 89BIO Inc. | Add +32.3% | 1.27% | +0.29 |
| LENZ Lenz Therapeutics Inc. | New | 0.28% | +0.28 |
| CGON CG Oncology Inc. | New | 0.27% | +0.27 |
| FULC Fulcrum Therapeutics Inc. | Add +6.9% | 0.81% | +0.24 |
| RGNX Regenxbio Inc. | New | 0.11% | +0.11 |
| EXAS Exact Sciences Corp. | New | 0.10% | +0.10 |
| TRML Tourmaline Bio Inc. | Add +86.0% | 0.25% | +0.09 |
| GKOS Glaukos Corp. | New | 0.08% | +0.08 |
| SGMT Sagimet Biosciences Inc. Class A | New | 0.08% | +0.08 |
| LRMR Larimar Therapeutics Inc. | New | 0.07% | +0.07 |
| XAIR Beyond Air Inc. | New | 0.03% | +0.03 |
| IMUX Immunic Inc. | Add +5.4% | 0.09% | −0.01 |
| SAGE Sage Therapeutics Inc. | Add +5.5% | 1.52% | −0.24 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +2.9% | 4.88% | −0.26 |
| AXSM Axsome Therapeutics Inc. | Add +0.1% | 5.29% | −0.29 |
| PEN Penumbra Inc. | Add +2.0% | 2.23% | −0.38 |
| TXG 10X Genomics Inc. Class A | Add +0.3% | 0.86% | −0.49 |
| ACAD Acadia Pharmaceuticals Inc. | Add +22.9% | 3.77% | −1.73 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 83 | $11.7B | MDGL, ARGX, PTCT, PTGX, CGON |
| Q1 2026 | 87 | $10.0B | MDGL, INSM, PTGX, PTCT, ARGX |
| Q4 2025 | 90 | $10.0B | MDGL, INSM, PTCT, ARGX, PTGX |
| Q3 2025 | 73 | $8.1B | MDGL, ARGX, RNAM, PTCT, INSM |
| Q2 2025 | 72 | $7.0B | MDGL, NTRA, PTCT, ARGX, PTGX |
| Q1 2025 | 67 | $6.5B | MDGL, ARGX, PTCT, NTRA, AXSM |
| Q4 2024 | 71 | $6.6B | MDGL, ARGX, NTRA, AXSM, PTCT |
| Q3 2024 | 67 | $6.9B | MDGL, AXSM, RNAM, ARGX, NTRA |
| Q2 2024 | 67 | $6.5B | MDGL, RCKT, AXSM, RNAM, ARGX |
| Q1 2024 | 68 | $6.8B | RCKT, IMCR, AXSM, RARE, BRKR |